Targets › CBP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). (UniProt, Q92793)
Open in Phaseline: the race on CBP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Opna Bio | OPN-6602 EP300 and CBP bromodomain inhibitor | EP300, CBP | Phase 1 | Relapsed Multiple Myeloma | Dec 2027 |
Relapsed Multiple Myeloma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.